Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 22 2014
Print

Financial Report: Charles River Laboratories



Published February 14, 2013
Charles River Laboratories

4Q Revenues: $280.1 million(-4%)

4Q Earnings: $18.5 million(-32%)

FY Revenues: $1.1 billion (-1%)

FY Earnings: $97.9 million(-11%)

Comments: Research Models and Services (RMS) segment sales were down 6% to $171.8 million in the quarter, driven by lower sales of research models, offset by Endotoxin sales and Microbial Detection (EMD) business, which included the acquisition of Accugenix. Preclinical Services (PCS) segment sales were flat at $108.3 million. For the year RMS sales were $695.1 million, down 2% and PCS sales were $434.4 million, down 1%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On